In this letter, Im going to show you what that mistake was, how it reframes the entire conversation around GLP-1-based weight loss drugs, and offer practical insights to minimize functional muscle loss while taking incretin-based weight loss drugs
tirzepatide also led to a mean body weight reduction of 18.1% from baseline, compared to 1.3% from baseline for placebo
17 In fact, 54% of all patents listed for GLP-1 products are for the delivery devices, not the drugs themselves
In clinical trials , Wegovy helped participants lose around 20 percent of their body weight over a 68-week period, along with diet and excercise When combined with healthy habits like regular exercise, nutritious meals, and sleep support, research shows that these results can often be maintained long term